AbbVie Takes Global Lead on Two Brise Migraine Programs
On Nov. 2, 2026, Brise Pharmaceuticals said AbbVie will lead worldwide development and commercialization of two preclinical migraine programs under their exclusive license agreement, which was entered in 2024. Brise will continue discovery work. The reported maximum transaction value differs between the materials: one gives up to $1.7 billion, while the company announcement gives up to US $757 million plus royalties on future sales.
Why it matters
AbbVie assumes global development and commercialization responsibilities for the two programs, while Brise retains discovery responsibilities. Payments are contingent on development, commercial, regulatory and sales milestones, with royalties tied to future sales.
Key facts
- 1The agreement covers two preclinical migraine programs, with AbbVie responsible for global development and commercialization and Brise responsible for discovery efforts. finance.yahoo.com
- 2Brise said it had already achieved several near-term milestones as of the Nov. 2, 2026 announcement. finance.yahoo.com
- 3The companies entered the exclusive license agreement in 2024. finance.yahoo.com
Open questions
- The materials report different maximum transaction values for the same agreement: up to $1.7 billion in material 1 versus up to US $757 million plus royalties on future sales in material 2.
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.